Related Experiment Video

Updated: Nov 27, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

876

Therapeutic development and current uses of BCL-2 inhibition

Andrew W Roberts1

  • 1Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia; and Victorian Comprehensive Cancer Centre, Melbourne, Australia.

Hematology. American Society of Hematology. Education Program
|December 4, 2020
PubMed

Insights

Venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor, offers a new treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Understanding its mechanism, resistance, and future development is crucial for optimizing this BH3-mimetic therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • B-cell lymphoma 2 (BCL2) protein regulates apoptosis and is overexpressed in hematological malignancies, promoting cancer cell survival.
  • Venetoclax represents a novel class of anticancer drugs known as BH3-mimetics, specifically targeting BCL2.
  • The drug is approved for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Purpose of the Study:

  • To review the development history and mechanism of action of venetoclax.
  • To summarize clinical evidence supporting venetoclax use in CLL and AML.
  • To explore resistance mechanisms and future directions for BH3-mimetic therapy.

Main Methods:

  • Literature review of venetoclax development and clinical trials.
  • Analysis of preclinical and clinical data on BCL2 inhibition.
  • Discussion of emerging resistance patterns and therapeutic strategies.

Main Results:

  • Venetoclax is the first approved selective BCL2 inhibitor and BH3-mimetic.
  • Evidence supports its efficacy in managing CLL and AML patients.
  • Mechanisms of resistance are being identified, informing future treatment approaches.

Conclusions:

  • Venetoclax offers a significant advancement in treating specific hematological cancers.
  • Understanding resistance is key to expanding the therapeutic potential of BCL2 inhibitors.
  • Future research should focus on overcoming resistance and refining venetoclax-based therapies.

More Related Videos

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.2K
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
899
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
315